

S. No.	Name of the Issuer: VIVRITI CAPITAL LIMITED (formerly known as Vivriti Capital Private Limited)	Last updated: February 15, 2024																																												
1	<p>Type of Issue: Public Issue by VIVRITI CAPITAL LIMITED (formerly known as Vivriti Capital Private Limited) ("VCL" or the "Company" or the "Issuer") of Secured, Rated, Listed, Redeemable, Non-Convertible Debentures of face value of ₹ 1,000 each ("NCDs") for an amount of ₹ 25,000 lakh ("Base Issue Size") with an option to retain oversubscription up to ₹ 25,000 lakh ("Green Shoe Option"), cumulatively aggregating up to 50,00,000 NCDs for an aggregate amount of up to ₹ 50,000 lakh ("Issue Size" or "Issue Limit") (the "Issue").</p> <p>The Company had filed the Prospectus dated August 8, 2023 with the Registrar of Companies, Tamil Nadu at Chennai, ("RoC"), the BSE Limited ("BSE") (the "Stock Exchange") and the Securities and Exchange Board of India ("SEBI").</p>																																													
2	<p>Issue size: ₹ 25,000 lakh ("Base Issue Size") with an option to retain oversubscription up to ₹ 25,000 lakh ("Green Shoe Option"), cumulatively aggregating up to 50,00,000 NCDs amounting to ₹ 50,000 lakh ("Issue Size" or "Issue Limit"). The Issuer has issued and allotted NCDs aggregating to ₹ 49,273.46 lakh. (Source: Minutes of the Meeting dated September 5, 2023 held between VCL; the Lead Manager; and the Registrar)</p>																																													
3	<p>Rating of instrument alongwith name of the rating agency</p> <p>(i) as disclosed in the offer document: [ICRA] A (Stable) by ICRA Limited and CARE A; Positive by CARE Ratings Limited</p> <p>(ii) at the end of 1st FY (March 31, 2024)*: NA</p> <p>(iii) at the end of 2nd FY (March 31, 2025)*: NA</p> <p>(iv) at the end of 3rd FY (March 31, 2026)*: NA</p> <p>Source: Prospectus dated August 8, 2023</p> <p>* Periods not available</p>																																													
4	<p>Whether the security created is adequate to ensure 100% asset cover for the debt securities: Yes (Source: Debenture Trust Deed dated September 6, 2023)</p>																																													
5	<p>Subscription level (number of times): After considering the not Banked and technical rejection cases, the Issue was subscribed 1.97 times of the Base Issue Size and 0.98 times of the overall Issue Size. (Source: Minutes of the Meeting dated September 5, 2023 held between VCL; the Lead Manager; and the Registrar)</p>																																													
6	<p>Financials of the issuer</p> <table border="1"> <thead> <tr> <th>Parameters</th> <th colspan="3">(In ₹ lakh)</th> </tr> <tr> <th></th> <th>FY 2024 ^(#)</th> <th>FY 2025 ^(#)</th> <th>FY 2026 ^(#)</th> </tr> </thead> <tbody> <tr> <td>Income from operations</td> <td>NA</td> <td>NA</td> <td>NA</td> </tr> <tr> <td>Net Profit for the period</td> <td>NA</td> <td>NA</td> <td>NA</td> </tr> <tr> <td>Paid-up equity share capital</td> <td>NA</td> <td>NA</td> <td>NA</td> </tr> <tr> <td>Reserves excluding revaluation reserves</td> <td>NA</td> <td>NA</td> <td>NA</td> </tr> </tbody> </table> <p>Note: (#) Periods not completed</p>		Parameters	(In ₹ lakh)				FY 2024 ^(#)	FY 2025 ^(#)	FY 2026 ^(#)	Income from operations	NA	NA	NA	Net Profit for the period	NA	NA	NA	Paid-up equity share capital	NA	NA	NA	Reserves excluding revaluation reserves	NA	NA	NA																				
Parameters	(In ₹ lakh)																																													
	FY 2024 ^(#)	FY 2025 ^(#)	FY 2026 ^(#)																																											
Income from operations	NA	NA	NA																																											
Net Profit for the period	NA	NA	NA																																											
Paid-up equity share capital	NA	NA	NA																																											
Reserves excluding revaluation reserves	NA	NA	NA																																											
7	<p>Status of the debt securities (whether traded, delisted, suspended by any stock exchange, etc.)</p> <p>(i) at the end of 1st FY (March 31, 2024)*: N.A.</p> <p>(ii) At the end of 2nd FY (March 31, 2025)*: N.A.</p> <p>(iii) At the end of 3rd FY (March 31, 2026)*: N.A.</p> <p>Note: Listing and trading permission granted by BSE on September 7, 2023 to commence trading with effect from September 8, 2023</p> <p>*Trading status not disclosed as reporting for the relevant fiscal years has not been completed</p>																																													
8	<p>Change, if any, in directors of issuer from the disclosures in the offer document</p> <table border="1"> <thead> <tr> <th>PARTICULARS</th> <th>NAME OF DIRECTOR</th> <th>APPOINTMENT/RESIGNATION</th> </tr> </thead> <tbody> <tr> <td>(i) At the end of 1st FY (March 31, 2024)*</td> <td>N.A.</td> <td>N.A.</td> </tr> <tr> <td>(ii) At the end of 2nd FY (March 31, 2025)*</td> <td>N.A.</td> <td>N.A.</td> </tr> <tr> <td>(iii) At the end of 3rd FY (March 31, 2026)*</td> <td>N.A.</td> <td>N.A.</td> </tr> </tbody> </table> <p>* Periods not available</p> <p>Updated as on February 15, 2024</p>		PARTICULARS	NAME OF DIRECTOR	APPOINTMENT/RESIGNATION	(i) At the end of 1st FY (March 31, 2024)*	N.A.	N.A.	(ii) At the end of 2nd FY (March 31, 2025)*	N.A.	N.A.	(iii) At the end of 3rd FY (March 31, 2026)*	N.A.	N.A.																																
PARTICULARS	NAME OF DIRECTOR	APPOINTMENT/RESIGNATION																																												
(i) At the end of 1st FY (March 31, 2024)*	N.A.	N.A.																																												
(ii) At the end of 2nd FY (March 31, 2025)*	N.A.	N.A.																																												
(iii) At the end of 3rd FY (March 31, 2026)*	N.A.	N.A.																																												
9	<p>Status of utilization of issue proceeds</p> <p>(i) as disclosed in the offer document: The Net Proceeds raised through this Issue will be utilised towards funding the following objects :-</p> <ol style="list-style-type: none"> For the purpose of onward lending, financing, and for repayment of interest and principal of existing borrowings of the Company # - Atleast 75% of amount proposed to be financed from Net Proceeds. For General Corporate Purposes* – Maximum of up to 25% of amount proposed to be financed from Net Proceeds <p>*The Net Proceeds will be first utilized towards the Objects mentioned above. The balance is proposed to be utilized for general corporate purposes, subject to such utilization not exceeding 25% of the amount raised in the Issue, in compliance with the SEBI NCS Regulations.</p> <p># Company shall not utilise the proceeds of this Issue towards payment of prepayment penalty, if any.</p> <p>Source: (Prospectus dated August 8, 2023)</p> <p>(ii) Actual utilization: Yes (Source: BSE Filing dated November 3, 2023: Statement of utilisation and material deviation in use of issue proceeds)</p> <p>(iii) Reasons for deviation, if any: NA</p>																																													
10	<p>Delay or default in payment of interest/ principal amount</p> <p>(i) Disclosures in the offer document on terms of issue: The Debenture Trustee will protect the interest of the NCD Holders in the event of default by company in regard to timely payment of interest and repayment of principal and they will take necessary action at company's cost. (Source: Prospectus dated August 8, 2023)</p> <p>(ii) Delay in payment from the due date: NA</p> <p>(iii) Reasons for delay/ non-payment, if any: NA</p>																																													
11	<p>Any other material information:</p> <table border="1"> <thead> <tr> <th>Date</th> <th>Announcement</th> </tr> </thead> <tbody> <tr> <td>26 September 2023</td> <td>Notice of AGM and Annual Report</td> </tr> <tr> <td>27 September 2023</td> <td>Intimation regarding the proceedings of 35th Extra ordinary General meeting</td> </tr> <tr> <td>30 September 2023</td> <td>Intimation of proceedings of 6th Annual General Meeting</td> </tr> <tr> <td>30 September 2023</td> <td>Closure of Trading Window</td> </tr> <tr> <td>10 October 2023</td> <td>Provisional ALM Statement for the period ended September 30, 2023</td> </tr> <tr> <td>14 October 2023</td> <td>ALM Statement for the period ended September 30, 2023</td> </tr> <tr> <td>21 October 2023</td> <td>Corporate Governance Report for quarter ended September 30, 2023</td> </tr> <tr> <td>28 October 2023</td> <td>Summary of Proceedings of 36th Extra-Ordinary General Meeting</td> </tr> <tr> <td>31 October 2023</td> <td>Intimation of Board Meeting to approve Unaudited Financial Results</td> </tr> <tr> <td>03 November 2023</td> <td>Outcome of Board Meeting - Approving: 1. Standalone Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023, along with the Limited review report 2. Statement indicating utilization of issue proceeds of non-convertible securities and statement of material deviation in the use of issue proceeds 3. Security Cover Certificate 4. Related Party Transactions for half year ended September 30, 2023</td> </tr> <tr> <td>09 November 2023</td> <td>Credit Rating by CRISIL Ratings Limited</td> </tr> <tr> <td>10 November 2023</td> <td>ALM Statement for period ended October 31, 2023</td> </tr> <tr> <td>13 December 2023</td> <td>Rating Upgrade from CARE Ratings Limited</td> </tr> <tr> <td>28 December 2023</td> <td>Outcome of Board Meeting - Reappointment of an Independent Director</td> </tr> <tr> <td>05 January 2024</td> <td>Outcome of EGM regarding re appointment of an Independent Director</td> </tr> <tr> <td>15 January 2024</td> <td>ALM Statement for period ended December 31, 2023</td> </tr> <tr> <td>20 January 2024</td> <td>Corporate Governance Report for quarter ended December 31, 2023</td> </tr> <tr> <td>03 February 2024</td> <td>Intimation of Board Meeting to approve Public Issue of NCDs and Unaudited Financial Results for quarter ended December 31, 2023</td> </tr> <tr> <td>07 February 2024</td> <td>Outcome of Board Meeting - Approving: 1. Unaudited Standalone Financial Results of the Company for the quarter ended December 31, 2023, along with the Limited review report 2. Statement indicating utilization of issue proceeds of non-convertible securities 3. Security Cover Certificate 4. Public Issue of NCDs 5. Other related matters</td> </tr> <tr> <td>10 February 2024</td> <td>ALM Statement for period ended January 31, 2024</td> </tr> <tr> <td>14 February 2024</td> <td>ALM Statement for period ended December 31, 2023</td> </tr> </tbody> </table>		Date	Announcement	26 September 2023	Notice of AGM and Annual Report	27 September 2023	Intimation regarding the proceedings of 35th Extra ordinary General meeting	30 September 2023	Intimation of proceedings of 6th Annual General Meeting	30 September 2023	Closure of Trading Window	10 October 2023	Provisional ALM Statement for the period ended September 30, 2023	14 October 2023	ALM Statement for the period ended September 30, 2023	21 October 2023	Corporate Governance Report for quarter ended September 30, 2023	28 October 2023	Summary of Proceedings of 36th Extra-Ordinary General Meeting	31 October 2023	Intimation of Board Meeting to approve Unaudited Financial Results	03 November 2023	Outcome of Board Meeting - Approving: 1. Standalone Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023, along with the Limited review report 2. Statement indicating utilization of issue proceeds of non-convertible securities and statement of material deviation in the use of issue proceeds 3. Security Cover Certificate 4. Related Party Transactions for half year ended September 30, 2023	09 November 2023	Credit Rating by CRISIL Ratings Limited	10 November 2023	ALM Statement for period ended October 31, 2023	13 December 2023	Rating Upgrade from CARE Ratings Limited	28 December 2023	Outcome of Board Meeting - Reappointment of an Independent Director	05 January 2024	Outcome of EGM regarding re appointment of an Independent Director	15 January 2024	ALM Statement for period ended December 31, 2023	20 January 2024	Corporate Governance Report for quarter ended December 31, 2023	03 February 2024	Intimation of Board Meeting to approve Public Issue of NCDs and Unaudited Financial Results for quarter ended December 31, 2023	07 February 2024	Outcome of Board Meeting - Approving: 1. Unaudited Standalone Financial Results of the Company for the quarter ended December 31, 2023, along with the Limited review report 2. Statement indicating utilization of issue proceeds of non-convertible securities 3. Security Cover Certificate 4. Public Issue of NCDs 5. Other related matters	10 February 2024	ALM Statement for period ended January 31, 2024	14 February 2024	ALM Statement for period ended December 31, 2023
Date	Announcement																																													
26 September 2023	Notice of AGM and Annual Report																																													
27 September 2023	Intimation regarding the proceedings of 35th Extra ordinary General meeting																																													
30 September 2023	Intimation of proceedings of 6th Annual General Meeting																																													
30 September 2023	Closure of Trading Window																																													
10 October 2023	Provisional ALM Statement for the period ended September 30, 2023																																													
14 October 2023	ALM Statement for the period ended September 30, 2023																																													
21 October 2023	Corporate Governance Report for quarter ended September 30, 2023																																													
28 October 2023	Summary of Proceedings of 36th Extra-Ordinary General Meeting																																													
31 October 2023	Intimation of Board Meeting to approve Unaudited Financial Results																																													
03 November 2023	Outcome of Board Meeting - Approving: 1. Standalone Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023, along with the Limited review report 2. Statement indicating utilization of issue proceeds of non-convertible securities and statement of material deviation in the use of issue proceeds 3. Security Cover Certificate 4. Related Party Transactions for half year ended September 30, 2023																																													
09 November 2023	Credit Rating by CRISIL Ratings Limited																																													
10 November 2023	ALM Statement for period ended October 31, 2023																																													
13 December 2023	Rating Upgrade from CARE Ratings Limited																																													
28 December 2023	Outcome of Board Meeting - Reappointment of an Independent Director																																													
05 January 2024	Outcome of EGM regarding re appointment of an Independent Director																																													
15 January 2024	ALM Statement for period ended December 31, 2023																																													
20 January 2024	Corporate Governance Report for quarter ended December 31, 2023																																													
03 February 2024	Intimation of Board Meeting to approve Public Issue of NCDs and Unaudited Financial Results for quarter ended December 31, 2023																																													
07 February 2024	Outcome of Board Meeting - Approving: 1. Unaudited Standalone Financial Results of the Company for the quarter ended December 31, 2023, along with the Limited review report 2. Statement indicating utilization of issue proceeds of non-convertible securities 3. Security Cover Certificate 4. Public Issue of NCDs 5. Other related matters																																													
10 February 2024	ALM Statement for period ended January 31, 2024																																													
14 February 2024	ALM Statement for period ended December 31, 2023																																													
<p>Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further details, please refer www.bseindia.com and / or www.nseindia.com.</p>																																														
<p>Disclaimer: The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.</p> <p>This information is gathered, inter-alia, from the Prospectus of VIVRITI CAPITAL LIMITED (formerly known as Vivriti Capital Private Limited) (the "Issuer"), as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") (the "Stock Exchange") from time to time, price-volume data available on the website of the Stock Exchange, other sources as disclosed herein and information / clarifications provided by the Issuer.</p> <p>Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.</p> <p>Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.</p>																																														